Natera Targets Keep Rising as Founders Sell Into Strength

NTRA is trading at $312.72, up 14% on the week and 16% on the month — but the most interesting development is that the Street is still catching up, while the people who built the company are selling.

The analyst revision wave that began on August 7 accelerated this week. Piper Sandler raised its Overweight target to $363.50 from $249, the largest dollar lift in the cohort. Guggenheim matched JPMorgan at $360, and Stephens lifted to $350. Every firm moving this week maintained a positive rating — no holds introduced, no downgrades. The consensus mean target has moved to roughly $328, now sitting above the current price at $312.72, which represents a meaningful shift from the prior note filed August 8, when the stock had already blown past the old consensus. The one persistent outlier is Wells Fargo, still at Equal-Weight with a $284 target — the only voice on the Street explicitly flagging the price as ahead of itself. The bull case centres on Signatera MRD volume growth and a rapidly expanding addressable market across oncology and reproductive health. The bear case is narrower but specific: competitive pressure in MRD from well-funded rivals, and execution risk as Natera bets aggressively on adjacent markets like newborn screening and pediatricians.

The founders are not waiting for further upgrades. On August 7 — the day after the blowout Q2 print — co-founder and Director Jonathan Sheena executed multiple sell transactions totalling roughly 8,750 shares, realising around $2.76 million across a series of trades priced between $308 and $321. Co-founder and Executive Chairman Matthew Rabinowitz sold a further 2,000 shares at $320.90 for approximately $642,000. Taken together, the 90-day net insider position is still positive — net sales of roughly $5.8 million in value — but the concentration of activity on the first trading day after the earnings-driven spike is notable. All transactions carry a significance score of 2 out of 10, consistent with routine plan-driven selling rather than a discretionary exit, but the timing amplifies the signal regardless.

Positioning in the lending market and options market has normalised sharply since the pre-earnings note. Availability is now extremely loose at 8,617% — over 142 million shares available to borrow against roughly 4.4 million shares short — and cost to borrow is negligible at 0.45%. Short interest itself fell 10% in a single session on August 11 to 3.2% of the float, unwinding the modest buildup that preceded earnings. The ORTEX short score has dropped to 34.3 from 35.5 earlier in the week, reflecting that reduced pressure. Options, meanwhile, have retreated from their pre-earnings defensiveness: the put/call ratio is at 1.00, about 1.6 standard deviations above its 20-day average of 0.86 — elevated but not extreme, and well below the 52-week high of 1.24. The defensive posture has eased, but options traders haven't fully switched to chasing upside either.

Among correlated peers, CAI surged 44% on the week and TWST added 24%, while VCEL dropped 4%. The broad biotech peer group was constructive, making NTRA's 14% week roughly in line with the stronger names in the basket rather than an outlier.

The next earnings event is scheduled for November 6. Between now and then, the story is whether the Street's revised targets — most clustered in the $340–$363 range — prove conservative again, or whether Wells Fargo's more cautious $284 level reasserts itself as the stock digests the post-earnings re-rating.